我国复方抗高血压药物的发展趋势探讨  

Trends in the development of new combination antihypertensive drugs in China

作　　者：华丛笑[1] 康彩练[1] 

机构地区：[1]国家食品药品监督管理局药品审评中心,北京100038

出　　处：《中国新药杂志》2010年第18期1652-1656,共5页Chinese Journal of New Drugs

摘　　要：近年来新作用机制的复方抗高血压药物不断涌现,其研发和临床应用逐渐增加。新型复方抗高血压药物能够增强降压疗效和/或减少不良反应,并使患者的服药依从性得到明显改善。因此,新型复方抗高血压药物的前景受到重视,开始成为复方降压药的主流。本文对我国复方抗高血压药物的发展趋势进行了分析探讨,提出应有更多的大规模临床试验进一步充实新型复方降压药的循证医学证据。由于复方抗高血压药物的临床地位趋于上升,随着降压治疗观念的转变,采用优化的初始联合用药或者复方制剂治疗可能成为新的趋势。Combination drugs of new mechanisms are constantly emerging,and the development and clinical application of these drugs have been significantly increased.New combination antihypertensive drugs can markedly improve compliance and antihypertensive efficacy as well as reduce adverse events.Therefore,new-mechanism antihypertensive drug combinations are becoming a mainstream of the combination therapies.This article described trends in the development of new-mechanism antihypertensive drug combinations in China.More large-scale clinical trials will enrich the medicine evidence of combination therapies.With the transformation of therapy conception,it is probable that optimized initial combination therapies may become a new prevalence.

关 键 词：高血压 复方抗高血压药物 发展趋势 

分 类 号：R972.4[医药卫生—药品]